Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Merck -- Ignore unavailable to you. Want to Upgrade?

To: Sonki who wrote (1057)	11/24/1998 11:33:00 AM
From: Anthony Wong	Respond to of 1580

Sonki, re. stock split, see the following excerpt from a Bloomberg article (seems it is Dec. 9 we should be looking at): Vioxx and a similar drug from Monsanto Co., Celebrex, could eventually have combined sales of $5 billion because they can treat pain and inflammation without irritating the stomach, analysts have said. Prospects for Vioxx have helped boost Merck's share price in the past month, leading to speculation it might announce a stock split at its Dec. 9 analyst meeting. ''It sure seems like they should,'' said Cynthia Beach, an analyst with Gerard Klauer Mattison, who has a ''buy'' on Merck. ''They're overdue for one.''